The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Novartis' Ultibro Breezhaler, or QVA149, as a treatment for chronic obstructive pulmonary disease. The once-daily drug is a combination of long-acting beta2-adrenergic agonist indacaterol and long-acting muscarinic antagonist glycopyrronium.

Full Story:

Related Summaries